Based on the results of previous reports suggesting the association of galectins with tumor malignancy in breast cancer, renal cancer, thyroid cancer, and other cancers [41], antibody therapy aiming at blocking either BST2 or Gal-8/-9 could be an option for anti-cancer therapy. Here, BST2 is linked to thyroid cancer.